乳腺癌是全球第二大癌症死亡原因。生物标志物的发现促进了对分子表型分析的理解的进步，因此在精确管理这种多样化疾病方面具有巨大潜力。尽管人们对生物标志物领域的兴趣日益浓厚，但只有少数乳腺癌生物标志物已知在临床上有用。因此，表征该领域生物标志物的成功率并研究缺陷的潜在原因非常重要。因此，我们的目标是通过跟踪与乳腺癌复发相关的预后生物标志物的进展来实现生物标志物翻译差距的定量表征。使用与乳腺癌复发生物标志物相关的关键词和网格标题在 Medline 和 Embase 数据库中进行了电子系统搜索（1940- 2023）。筛选了摘要，并选择了涉及乳腺癌复发生物标志物的主要临床研究。在确定相关文献后，我们提取了生物标志物名称、发表日期和期刊名称。所有分析均使用 IBM SPSS Statistics 和 GraphPad prism（美国加利福尼亚州拉霍亚）进行。共识别出 19,195 篇文章，其中 4597 篇文章报告了与复发相关的乳腺癌生物标志物。数据提取后，鉴定出了 2437 个个体生物标志物。其中，目前推荐临床使用的有 23 种，仅占所有已发现生物标志物的 0.94%。这项研究首次描述了复发相关乳腺癌生物标志物领域的转化差距，表明仅 0.94%已确定的生物标志物被推荐用于临床。这表明生物标志物研究领域存在明显的障碍，并强调需要有一条从生物标志物发现到实施的更清晰路线。© 2024。Crown。

Breast cancer is the second most common cause of cancer mortality worldwide. Biomarker discovery has led to advances in understanding molecular phenotyping and thus has a great potential for precision management of this diverse disease. Despite increased interest in the biomarker field, only a small number of breast cancer biomarkers are known to be clinically useful. Therefore, it is very important to characterise the success rate of biomarkers in this field and study potential reasons for the deficit. We therefore aim to achieve quantitative characterisation of the biomarker translation gap by tracking the progress of prognostic biomarkers associated with breast cancer recurrence.An electronic systematic search was conducted in Medline and Embase databases using keywords and mesh headings associated with breast cancer recurrence biomarkers (1940-2023). Abstracts were screened, and primary clinical studies involving breast cancer recurrence biomarkers were selected. Upon identification of relevant literature, we extracted the biomarker name, date of publication and journal name. All analyses were performed using IBM SPSS Statistics and GraphPad prism (La Jolla, California, USA).A total of 19,195 articles were identified, from which 4597 articles reported breast cancer biomarkers associated with recurrence. Upon data extraction, 2437 individual biomarkers were identified. Out of these, 23 are currently recommended for clinical use, which corresponds to only 0.94% of all discovered biomarkers.This study characterised for the first time the translational gap in the field of recurrence-related breast cancer biomarkers, indicating that only 0.94% of identified biomarkers were recommended for clinical use. This denotes an evident barrier in the biomarker research field and emphasises the need for a clearer route from biomarker discovery through to implementation.© 2024. Crown.